BIOLIFE SOLUTIONS INC [BLFS] - BioLife Solutions / Repligen merger
Repligen Corporation will acquire BioLife Solutions Inc. for $11.25 in cash and 0.1442 shares of Repligen's common stock per share, under a definitive merger agreement approved by both companies' boards.
Why this matters
BioLife Solutions Inc., incorporated in Delaware, operates in the electromedical and electrotherapeutic apparatus industry, providing biopreservation media and cell processing tools essential for biologics manufacturing. Repligen Corporation has entered into a definitive merger agreement to acquire BioLife Solutions for approximately $1.5 billion, with consideration comprising 64% in Repligen common stock and 36% in cash. This strategic move aims to enhance Repligen's position in the cell therapy market by integrating BioLife's differentiated product portfolio and expanding its solutions offering to cell therapy customers. Under the terms of the agreement, BioLife shareholders will receive $11.25 in cash and 0.1442 shares of Repligen's common stock per share, with the transaction subject to customary closing conditions.